M&As this week: Allergan, Cannabis Care Canada

22nd September 2016 (Last Updated September 22nd, 2016 18:30)

Allergan plans to expand its gastrointestinal research and development (R&D) pipeline and strengthen its position in non-alcoholic steatohepatitis through the acquisition of Tobira Therapeutics.

Allergan plans to expand its gastrointestinal research and development (R&D) pipeline and strengthen its position in non-alcoholic steatohepatitis through the acquisition of Tobira Therapeutics.

The company expects to complete the transaction by October 2016 at a cost of up to $1.6bn.

Cannabis Care Canada Inc has announced its acquirement of Mettrum Ltd from Mettrum Health Corporation for a purchase consideration of $5.3m.

Covington & Burling is acting as the legal advisor, while Centerview Partners and Citigroup Inc are acting as financial advisors to Allergan. SKadden, Arps, Slate, Meagher & Flom and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian are acting as legal advisors to Tobira Therapuetics.

Cannabis Care Canada Inc has announced its acquirement of Mettrum Ltd from Mettrum Health Corporation for a purchase consideration of $5.3m.

Pursuant to the acquisition, Mettrum will become a wholly owned subsidiary of CCC and will be renamed as Starseed Medicinal Inc.

The acquisition will allow Cannabis Care Canada to make cannabis treatment accessible to all of its members and their families.